Trial Profile
A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms 10v13vPCV Trial; PCV1103
- 19 Jul 2023 Results assessing pneumococcal carriage rates, serotype distribution, and antimicrobial susceptibility in PNG children after vaccination, published in the Vaccine
- 09 Aug 2021 Results (n=219) comparing vaccine and non-vaccine serotype carriage density in PCV13-vaccinated and unvaccinated Papua New Guinean infants from this and pneumonia and meningitis aetiology study published in the Vaccine
- 20 May 2021 Results (n=101) published in the Vaccine